Apogee Therapeutics (APGE) Expected to Announce Earnings on Tuesday

Apogee Therapeutics (NASDAQ:APGE) will likely be announcing its earnings results before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.94) per share for the quarter.

Apogee Therapeutics Stock Performance

Shares of NASDAQ:APGE opened at $33.37 on Tuesday. Apogee Therapeutics has a 52 week low of $32.46 and a 52 week high of $72.29. The company has a 50-day moving average price of $41.56 and a 200 day moving average price of $47.75.

Wall Street Analyst Weigh In

APGE has been the topic of a number of analyst reports. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $89.00 price target on the stock. Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 target price on the stock. Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Finally, Wedbush raised their price objective on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday, December 2nd. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $89.71.

Insider Activity

In other news, CEO Michael Thomas Henderson sold 15,000 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $46.58, for a total value of $698,700.00. Following the sale, the chief executive officer now directly owns 1,324,487 shares in the company, valued at $61,694,604.46. This represents a 1.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark C. Mckenna acquired 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $49.54 per share, with a total value of $990,800.00. Following the completion of the transaction, the director now directly owns 20,000 shares in the company, valued at approximately $990,800. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 63,810 shares of company stock worth $2,903,556 over the last 90 days. 36.10% of the stock is currently owned by corporate insiders.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.